ES2162620T3 - Nuevo uso de los acidos grasos omega 3. - Google Patents

Nuevo uso de los acidos grasos omega 3.

Info

Publication number
ES2162620T3
ES2162620T3 ES93905710T ES93905710T ES2162620T3 ES 2162620 T3 ES2162620 T3 ES 2162620T3 ES 93905710 T ES93905710 T ES 93905710T ES 93905710 T ES93905710 T ES 93905710T ES 2162620 T3 ES2162620 T3 ES 2162620T3
Authority
ES
Spain
Prior art keywords
pct
preparations
fatty acids
omega
dic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93905710T
Other languages
English (en)
Inventor
Nils Egberg
Carin Larsson-Backstrom
Jan Jakobsson
Rolf Lundh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresenius Kabi AB
Original Assignee
Fresenius Kabi AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi AB filed Critical Fresenius Kabi AB
Application granted granted Critical
Publication of ES2162620T3 publication Critical patent/ES2162620T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A PREPARACIONES QUE CONTIENEN ACIDOS OMEGA-3-GRASOS PARA EL TRATAMIENTO DE LA COAGULACION INTRAVASCULAR DISEMINADA (DIC) Y DE LOS SINTOMAS RELACIONADOS CON LA DIC, ASI COMO A TALES PREPARACIONES PARA REDUCIR UN AUMENTO PATOLOGICO DE LA PRESION ARTERIAL PULMONAR (PAP). LAS PREPARACIONES PUEDEN SER A MODO DE EMULSIONES, O AEROSOLES A INHALAR, DE UN ACEITE O FOSFOLIPIDOS U OTROS DERIVADOS O SALES DE ACIDOS OMEGA-3-GRASOS DE ORIGEN MARINO Y/O VEGETAL CON UN CONTENIDO SIGNIFICATIVO DE ACIDOS OMEGA-3-GRASOS. LAS PREPARACIONES PUEDEN SER TAMBIEN A MODO DE PASTILLAS O CAPSULAS DE USO ORAL.
ES93905710T 1992-02-24 1993-02-23 Nuevo uso de los acidos grasos omega 3. Expired - Lifetime ES2162620T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9200541A SE9200541D0 (sv) 1992-02-24 1992-02-24 New usee of omega-3-fatty acids

Publications (1)

Publication Number Publication Date
ES2162620T3 true ES2162620T3 (es) 2002-01-01

Family

ID=20385410

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93905710T Expired - Lifetime ES2162620T3 (es) 1992-02-24 1993-02-23 Nuevo uso de los acidos grasos omega 3.

Country Status (13)

Country Link
US (2) US5747533A (es)
EP (1) EP0627918B1 (es)
JP (1) JP3559280B2 (es)
AT (1) ATE207744T1 (es)
AU (1) AU671438B2 (es)
CA (1) CA2117535A1 (es)
DE (1) DE69331051T2 (es)
DK (1) DK0627918T3 (es)
ES (1) ES2162620T3 (es)
NO (1) NO309704B1 (es)
SE (1) SE9200541D0 (es)
SG (1) SG46238A1 (es)
WO (1) WO1993016691A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0987176A (ja) * 1995-09-26 1997-03-31 Shiseido Co Ltd 糸球体腎炎抑制剤
WO1998057628A1 (fr) * 1997-06-16 1998-12-23 Nippon Suisan Kaisha, Ltd. Composition capable de supprimer le facteur de risque pendant l'exercice
US6054481A (en) * 1998-01-21 2000-04-25 Fideline Pig appeasing pheromones for enhancing weight gain in a mammal
US6077867A (en) 1998-01-21 2000-06-20 Fideline Pig appeasing pheromones to decrease stress, anxiety and aggressiveness
JP4754688B2 (ja) * 1998-01-21 2011-08-24 フィドゥラン ストレス、不安及び攻撃性を低減するブタ鎮静フェロモン
CA2388754C (en) * 1999-10-13 2010-07-13 Marco A. Chacon Therapeutic intervention to mimic the effect of caloric restriction
FR2804023B1 (fr) * 2000-01-26 2002-09-20 Johnson & Johnson Consumer Fr Complement nutritionnel a base d'huile de pepins de cassis
WO2002069964A1 (en) * 2001-03-05 2002-09-12 Ernest Stephen P Enteral formulation
US8729124B2 (en) * 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
US7323206B1 (en) 2003-03-04 2008-01-29 B. Braun Medical Inc. Reagents and methods for all-in-one total parenteral nutrition for neonates and infants
US20060067976A1 (en) 2004-09-28 2006-03-30 Atrium Medical Corporation Formation of barrier layer
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9592324B2 (en) 2006-11-06 2017-03-14 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US20060088596A1 (en) 2004-09-28 2006-04-27 Atrium Medical Corporation Solubilizing a drug for use in a coating
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
AU2006273696B2 (en) * 2005-06-24 2012-08-30 Drugrecure Aps Airway administration of activated protein C in inflammatory conditions affecting the respiratory tract
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
JP2009525992A (ja) * 2006-02-10 2009-07-16 スポーツコム デンマーク アプス コーティングを施した錠剤、その製造方法、及び関連する使用
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
US20080207756A1 (en) * 2007-02-27 2008-08-28 Atrium Medical Corporation Bio-absorbable oil suspension
CA2692394A1 (en) * 2007-07-06 2009-01-15 Seth J. Baum Fatty acid compositions and methods of use
EP2214481B1 (en) 2007-10-15 2019-05-01 United Animal Health, Inc. Method for increasing performance of offspring
EP2211881A4 (en) * 2007-11-01 2012-01-04 Wake Forest University School Of Medicine COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING DISEASES AFFECTING MAMMALS
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US20100323028A1 (en) * 2007-11-30 2010-12-23 Jbs United, Inc. Method and composition for treating pulmonary hemorrhage
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US20110045050A1 (en) * 2009-08-24 2011-02-24 Atrium Medical Corporation Nanoemulsion formulations for direct delivery
US20110200645A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Free Fatty Acid Emulsions
WO2011103514A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha triglyceride emulsions
EP2593141B1 (en) 2010-07-16 2018-07-04 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
US20210176999A1 (en) 2011-04-17 2021-06-17 Omega Foods, LLC Prepared foods having high efficacy omega-6/omega-3 balanced polyunsaturated fatty acids
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
US10183044B2 (en) * 2015-05-15 2019-01-22 P Tech, Llc Systems and methods for thrombosis prevention
US9655847B1 (en) * 2016-07-18 2017-05-23 National Guard Health Affairs Therapeutic liposome and method of treating a subject having cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752618A (en) * 1984-07-12 1988-06-21 New England Deaconess Hospital Method of minimizing efects of infection through diet
US4678808A (en) * 1985-10-15 1987-07-07 Baxter Travenol Laboratories, Inc. Rapid acting intravenous emulsions of omega-3 fatty acid esters
AU596880B2 (en) * 1986-09-17 1990-05-17 Clintec Nutrition Company Liquid nutritional compositions
DE3719097C1 (de) * 1987-06-06 1988-06-09 Fratzer Uwe Arzneimittel,enthaltend Eicosapentaensaeure und Docosahexaensaeure als ungesaettigte Fettsaeuren sowie Vitamin E
GB8729751D0 (en) * 1987-12-21 1988-02-03 Norsk Hydro As Feed additive & feed containing such additive
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5223285A (en) * 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients

Also Published As

Publication number Publication date
AU671438B2 (en) 1996-08-29
CA2117535A1 (en) 1993-09-02
ATE207744T1 (de) 2001-11-15
SG46238A1 (en) 1998-02-20
JPH07507766A (ja) 1995-08-31
SE9200541D0 (sv) 1992-02-24
NO309704B1 (no) 2001-03-19
NO943102D0 (no) 1994-08-23
DE69331051T2 (de) 2002-06-13
DE69331051D1 (de) 2001-12-06
WO1993016691A1 (en) 1993-09-02
DK0627918T3 (da) 2002-01-14
JP3559280B2 (ja) 2004-08-25
US5731346A (en) 1998-03-24
AU3652993A (en) 1993-09-13
EP0627918B1 (en) 2001-10-31
EP0627918A1 (en) 1994-12-14
US5747533A (en) 1998-05-05
NO943102L (no) 1994-10-21

Similar Documents

Publication Publication Date Title
ES2162620T3 (es) Nuevo uso de los acidos grasos omega 3.
ATE192928T1 (de) Lipide zur epidermalen befeuchtung und zur wiederherstellung der barrierefunktion
DE59009351D1 (de) Neue arylpyridazine, ihre herstellung, verwendung und sie enthaltende arzneimittel.
FR2762993B1 (fr) Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
DE69418465T2 (de) Persönliches reinigungsmittel
PT100524A (pt) Emulsoes aquosas de oleos de origem vegetal e/ou marinha contendo fosfolipidos e composicoes que as contem
PT1229800E (pt) Emulsao contendo agua e oleo
ES2177642T3 (es) Uso de ciertos derivados de acido metanobisfosfonico para prevenir el desprendimiento y la migracion de protesis.
DE50012804D1 (de) Kosmetische und dermatologische Zubereitungen auf der Grundlage von O/W-Emulsionen
KR870700599A (ko) 카르복실산유도체, 그의 제조방법, 이화합물을 함유한 약제조성물 및 그의 용도
ES2180591T3 (es) Barra limpiadora de la piel que tiene cocoil-isetionato de primera destilacion.
Brown et al. Dietary protein intake and the glomerular adaptations to partial nephrectomy in dogs
ATE233246T1 (de) Hydantoinderivate als zwischenprodukte für pharmazeutische wirkstoffe
AU600502B2 (en) Body lubricating and cleansing fluid
MX9300707A (es) Composiciones liposomaticas topicas que comprenden piroxicam y procedimiento para su preparacion.
SE8801710L (sv) New ophtalmological composition of matter
CA1266238C (en) SOAPS AND SHAMPOOS CONTAINING BIO-EMULSIFIERS
DE69329687D1 (de) Verwendung von aspirin zur herstellung eines arzneimittels zur verbesserung fer blutperfusion des uterus
FR2363324A1 (fr) Solutions aqueuses ou hydroalcooliques stables d'essences parfumees ou de medicaments solubles dans l'huile
DE3584131D1 (de) Methode zur behandlung der antidiurese.
DE58906606D1 (de) Optisch aktive Rhodiumkomplexe von 3,4-Bis(diarylphosphino)-pyrrolidinen und ihre Verwendung zur Herstellung von Phosphinothricin durch asymmetrische Hydrierung.
DK0746551T3 (da) Optisk rene 4-aryl-2-hydroxytetronsyrer
ES2074264T3 (es) Esteres de aminoacidos de la hidroquinona, su procedimiento de preparacion y composiciones farmaceuticas o cosmeticas que los contienen.
NO975155D0 (no) Anvendelse av forskolin eller ekstakter inneholdende denne ved fremstilling av et medikament for behandling av alkoholavhengighet
JPS57209218A (en) Antithrombotic

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 627918

Country of ref document: ES